Recent analyses on retatrutide, a dual agonist for incretin hormone and gastric inhibitory polypeptide, indicate promising findings in treating obesity and type 2 glucose intolerance. Early data from clinical assessments point to considerable reductions in body weight and bettered glucose control. Additional examination is centered on long-term har